Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — Corporate Update (September 2025)
25 slides from Crinetics Pharmaceuticals's corporate update, Sep 25, 2025
Slide 1: PALSONIFY (paltusotine) FDA Approval
September 25, 2025 PALSONIFY (paltusotine) FDA Approval
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statement
Slide 3: Introductory Remarks
INTRODUCTORY REMARKS Scott Struthers, Ph.D. Founder & Chief Executive Officer CRINETICS PHARMACEUTICALS | 3
Slide 4: Our Mission
To be the world’s leading endocrine company that Our Mission: consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives Acromegaly Carcinoid Syndrome Congenital Adrenal Hyperplasia ACTH-Dependent Cushing’s Syndrome Tony Ellen Wendy NETs and SS
Slide 5: Acromegaly Symptoms Take a Toll on Patients
Acromegaly Symptoms Take a Toll on Patients Acromegaly is a rare chronic disease caused by a pituitary adenoma that secretes excess GH, resulting in hypersecretion of IGF-I1,2 Effects of Prolonged Exposure to IGF-I and GH1,2 Patient Symptoms3-4 LOCAL TUMOR EFFECTS PHYSICAL CHANGES Headache | Visual
Slide 6: Acromegaly is a cage... patient quote
“ Acromegaly is a cage... I've been dealing with this a long time. And there are medicines out there that will let you live life somewhat...I'm not symptom-free…If I was better controlled, I wouldn’t have to take that 30-minute nap when I get home or feel like my head is dragging. Because of acromeg
Slide 7: Now FDA Approved: A New Era in Acromegaly Treatment
NOW FDA APPROVED A New Era in Acromegaly Treatment CRINETICS PHARMACEUTICALS | 7
Slide 8: Clinical Data Review
CLINICAL DATA REVIEW Dana Pizzuti, M.D. Chief Medical Officer CRINETICS PHARMACEUTICALS | 8
Slide 9: PALSONIFY's Broad Label Supported by Robust Clinical Database
PALSONIFY’s Broad Label Supported by Robust Clinical Database Highlights of Prescribing Information Prescribing Information and Instructions for Use of PALSONIFY are available here CRINETICS PHARMACEUTICALS | 9
Slide 10: Biochemical Control in Switch Patients
In Phase 3 Studies, PALSONIFY Achieved Rapid, Reliable and Consistent Biochemical Control in Switch Patients Patients Switching From PALSONIFY Treatment Maintained IGF-1 Control Standard-of-Care in Patients who Switched from SRL Injections 2.0 Mean (±SE) IGF-I (× ULN) 83% 1.5 1.0 p<0.0001 4% 0.5 Pal
Slide 11: Biochemical Control in Naïve Patients
In Phase 3 Studies, PALSONIFY Achieved Rapid, Reliable and Consistent Biochemical Control in Naïve Patients Non-Pharmacologically- Percent Change from Baseline in IGF-1 Level by Visit Treated Patients 10 PALSONIFY (N=54) Placebo (N=57) IGF-1 Mean Percent Change 0 from Baseline (± SE) 56% -10 Rapid 9
Slide 12: Long-Term, Stable Biochemical Control Across Acromegaly Patients
PALSONIFY Treatment Results in Long-Term, Stable Biochemical Control Across a Range of Acromegaly Patients Evolve/ Edge ACROBAT Advance 3.0 LA- Wash SRL -out Median IGF-I ± IQR IGF-I (x ULN) 2.0 1.0 ULN 4 years 0.0 W3 W15 W39 W51 W77 W103 W129 W155 W181 W207 N 43 43 43 42 39 40 37 37 35 33 28 20 PAT
Slide 13: Consistent Control of Symptoms and Reduced Exacerbations
In Phase 3 Studies, PALSONIFY Achieved Consistent Control of Symptoms and Reduced Frequency of Symptom Exacerbations Label includes reduced severity of 7 key symptoms in both randomized trials Symptom exacerbation frequency continued to decline throughout the 9-month study 35 30 Exacerbation Rate 25
Slide 14: Well-Tolerated with No Severe or Serious Adverse Events
PALSONIFY was Well-Tolerated with No Severe or Serious Adverse Events Key safety outcomes from the randomized control period of Phase 3 studies • No serious adverse events None occurred with PALSONIFY vs 2.4% with placebo • GI AEs resolved Most GI AEs occurred within the first 2 months (median durat
Slide 15: Commercial Launch Strategy
COMMERCIAL LAUNCH STRATEGY Isabel Kalofonos Chief Commercial Officer CRINETICS PHARMACEUTICALS | 15
Slide 16: Four Pillars to Optimize the Launch of PALSONIFY
Four Pillars to Optimize the Launch of PALSONIFY ACTIVATE ADOPT ACCESS ADHERE SHIFT THE WIN ON ENSURE DRIVE ADHERENCE MINDSET EFFICACY ACCESS Success isn’t just Switch and naïve Removing friction to With the right about IGF-1 control, patients deserve a help more patients support, patients it’s abou
Slide 17: Experienced Team in Place with Comprehensive Engagement Plan
Experienced Team in Place with Comprehensive Engagement Plan 36 Sales Team Sales Talent Metrics 19.7 in pharma/biotech years Mean years of experience 14 Medical Science Liaisons 9.2 in rare disease 8.7 in endocrinology years years 5 Nurse Educators 6 CrinetiCARE Specialists ~3,600 ~1,800 45 4 Field
Slide 18: Acromegaly Patient Reach
Acromegaly Patient Reach 36,000 People Living with 11,500 Actively Managed and Acromegaly in the US Addressable in Short-Term 7,500 No Active Follow-up 15% 40% Treatment Treatment Discontinued Naïve 17,000+ Undiagnosed 20% 11,500 Other Therapies Actively 25% Managed Injectable SRL 1,500/yr diagnosed
Slide 19: Education and Engagement Required to Empower Patients
Education and Engagement Required to Empower Patients to Demand More PATIENT ACTIVATION ACROMEGALY REALITY Disease education campaign to raise awareness of the lived realities of acromegaly and support earlier recognition and diagnosis CrinetiCARE Comprehensive patient support services to assist wit
Slide 20: Pre-Launch Engagement with Payers
Pre-Launch Engagement with Payers to Facilitate Post-Launch Formulary Access Strong value proposition to payers includes: Unprecedented Safety and Efficacy Maintain Control Ability to achieve rapid biochemical and Limit patient and societal burden symptom control based on Phase 3 data of uncontrolle
Slide 21: Supporting Patients at Every Step of Their Journey
Supporting Patients at Every Step of Their Journey Quickstart Program (Short-term) Commercial Payer MD Finder Co-pay Program Customized Adherence Patient Assistance Program and Compliance Program (Long-term) Live Nurse Support Patient Insurance Support Patient Support Center *All CrinetiCARE program
Slide 22: A New Era in Acromegaly Has Started
A New Era in Acromegaly Has Started Palsonify is here to transform acromegaly care Broad Label and Strong Data ” Patient Focus Experienced Team Tony, living with acromegaly
Slide 23: Closing Remarks
CLOSING REMARKS Scott Struthers, Ph.D. Founder & Chief Executive Officer CRINETICS PHARMACEUTICALS | 23
Slide 24: Palsonify is Just the Beginning: Building the Foundation for Our Pipeline
Palsonify is Just the Beginning: Building the Foundation for Our Pipeline Program IND- Discovery Phase 1 Phase 2 Phase 3 Registration Approved Enabling Partners Acromegaly (US) Paltusotine (SST2 agonist) Acromegaly (EU) Carcinoid syndrome Japan Development and Commercialization Congenital adrenal hy
Slide 25: Thank You
‘Crinetics armaceutica THANK YOU Q&A
Crinetics Pharmaceuticals — Corporate Update (September 2025) on 6ix